A research institute in United States conducts a clinical trial of Pilot Study of 89Zr Panitumumab in Pancreas Cancer.

Stanford University is recruiting patients for the clinical trial of Pilot Study of 89-Zr Panitumumab in Pancreas Cancer.

The main purpose of the study is to assess the safety of 89Zr-panitumumab as a molecular imaging agent in patients with (metastatic) pancreas cancer.

The researchers plan that March 26, 2021 will be the study start date. The indicative completion of the clinical trial will be expected in March 2023.

Among primary outcome measures are the Safety of 89Zr-panitumumab as a molecular imaging agent and Safety is defined by the number of CTCAE v5 grade 2 or higher adverse events by Day 7 determined that are significant, definitely, probably or possibly related to 89Zr-panitumumab. Safety data will be summarized by grade, severity, and type.

The study will take place at the Stanford University, Stanford, California, United States.

Confirmed diagnosis of pancreatic cancer. Exclusion Criteria: - Myocardial infarction (MI); cerebrovascular accident (CVA); uncontrolled congestive heart failure (CHF); significant liver disease; or unstable angina within 6 months prior to enrollment. - History of infusion reactions to monoclonal antibody therapies. - Pregnant or breastfeeding. - Subjects receiving Class IA (quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents. - Subjects with a history or evidence of interstitial pneumonitis or pulmonary fibrosis. - Severe renal disease or anuria. - Known hypersensitivity to deferoxamine or any of its components can be enrolled into this research.

There are a number of conditions that do not allow participation, such as:

• Myocardial infarction (MI); cerebrovascular accident (CVA); uncontrolled congestive heart failure (CHF); significant liver disease; or unstable angina within 6 months prior to enrollment. - History of infusion reactions to monoclonal antibody therapies. - Pregnant or breastfeeding. - Subjects receiving Class IA (quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents. - Subjects with a history or evidence of interstitial pneumonitis or pulmonary fibrosis. - Severe renal disease or anuria. - Known hypersensitivity to deferoxamine or any of its components.

The page dedicated to this clinical trial can be found here: https://ichgcp.net/clinical-trials-registry/NCT04833959